
    
      There have been no standard treatment in non-clear cell renal cell carcinoma. Retrospective
      studies showed sunitinib or sorafenib might be active in non-clear cell renal cell carcinoma,
      especially papillary type and chromophobe type.

      This study is to evaluate efficacy and safety of sunitinib in this group of patients.
    
  